Movatterモバイル変換


[0]ホーム

URL:


AU4652100A - Controlled delivery of bisphosphonates - Google Patents

Controlled delivery of bisphosphonates

Info

Publication number
AU4652100A
AU4652100AAU46521/00AAU4652100AAU4652100AAU 4652100 AAU4652100 AAU 4652100AAU 46521/00 AAU46521/00 AAU 46521/00AAU 4652100 AAU4652100 AAU 4652100AAU 4652100 AAU4652100 AAU 4652100A
Authority
AU
Australia
Prior art keywords
bisphosphonates
controlled delivery
delivery
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46521/00A
Inventor
Petr Kuzma
Agis Kydonieus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HYDROMED SCIENCES A DIVISION OF GP STRATEGIES Corp
Original Assignee
HYDROMED SCIENCES A DIVISION O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HYDROMED SCIENCES A DIVISION OfiledCriticalHYDROMED SCIENCES A DIVISION O
Publication of AU4652100ApublicationCriticalpatent/AU4652100A/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

AU46521/00A1999-04-222000-04-19Controlled delivery of bisphosphonatesAbandonedAU4652100A (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US13072899P1999-04-221999-04-22
US601307281999-04-22
PCT/US2000/010696WO2000064516A1 (en)1999-04-222000-04-19Controlled delivery of bisphosphonates

Publications (1)

Publication NumberPublication Date
AU4652100Atrue AU4652100A (en)2000-11-10

Family

ID=22446043

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU46521/00AAbandonedAU4652100A (en)1999-04-222000-04-19Controlled delivery of bisphosphonates

Country Status (4)

CountryLink
EP (1)EP1210138A4 (en)
AU (1)AU4652100A (en)
CA (1)CA2370769A1 (en)
WO (1)WO2000064516A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6984400B2 (en)1998-07-142006-01-10Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en)1998-07-141999-03-12Yissum Res Dev CoCompositions for inhibition and treatment of restinosis
US7008645B2 (en)1998-07-142006-03-07Yissum Research Development Company Of The Hebrew University Of JerusalemMethod of inhibiting restenosis using bisphosphonates
FR2803521B1 (en)*2000-01-122002-10-25Ceva Sante Animale USE OF TILUDRONIC ACID AND ITS DERIVATIVES IN POULTRY FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR PREVENTING AND TREATING OSTEOPOROSIS
US7829074B2 (en)2001-10-182010-11-09Nektar TherapeuticsHydroxypatite-targeting poly(ethylene glycol) and related polymers
US20020151876A1 (en)*2001-02-072002-10-17Tai-Wah ChanDevices and methods for management of bone density
KR20020080018A (en)*2001-04-102002-10-23한국화학연구원A controlled/sustained implant delivery containing bisphosphonate
US10517883B2 (en)2003-06-272019-12-31Zuli Holdings Ltd.Method of treating acute myocardial infarction
FI20031120A0 (en)*2003-07-312003-07-31Bci Bioabsorbable Concepts Ltd Multifunctional implant device
EP1508343B1 (en)*2003-08-212015-11-04AddBIO ABBisphosponate coated implant device and method therefor
WO2010111627A1 (en)*2009-03-262010-09-30Psivida Us, Inc.Implantable formulations of bisphosphonic acids
CN102573809B (en)2009-07-312017-07-21格兰泰股份有限公司Method for crystallising and bioavilability
US9169279B2 (en)2009-07-312015-10-27Thar Pharmaceuticals, Inc.Crystallization method and bioavailability
US20160016982A1 (en)2009-07-312016-01-21Thar Pharmaceuticals, Inc.Crystallization method and bioavailability
US20130064861A1 (en)*2010-02-172013-03-14Zvi SchwartzCompositions and methods for modifying in vivo calcification of hydrogels
US9340565B2 (en)2010-11-242016-05-17Thar Pharmaceuticals, Inc.Crystalline forms
US9993427B2 (en)2013-03-142018-06-12Biorest Ltd.Liposome formulation and manufacture
JO3394B1 (en)*2014-07-042019-10-20Osteo Pharma B VCompositions and products for use in the treatment of bone fractures and defects
US10195218B2 (en)2016-05-312019-02-05Grunenthal GmbhCrystallization method and bioavailability
US12377149B2 (en)*2018-06-012025-08-05The University Of North Carolina At Chapel HillInjectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3D printing bioink

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4753652A (en)*1984-05-041988-06-28Children's Medical Center CorporationBiomaterial implants which resist calcification
US5196409A (en)*1989-08-201993-03-23Yissum, Research Development Company Of The Hebrew University Of JerusalemBisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
CA2151240A1 (en)*1992-12-231994-07-07Donna T. WhitefordBiophosphonate/estrogen therapy for treating and preventing bone loss
FI92465C (en)*1993-04-141994-11-25Risto Tapani Lehtinen A method for handling endo-osteal materials
US5646134A (en)*1994-04-211997-07-08Merck & Co., Inc.Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JP3476930B2 (en)*1994-11-162003-12-10オリンパス株式会社 Biological implants
EP0831756A1 (en)*1995-06-061998-04-01Merck & Co., Inc.Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
US5898038A (en)*1996-03-191999-04-27Board Of Regents, The University Of Texas SystemTreatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
GB2324726A (en)*1997-05-011998-11-04Merck & Co IncCombination Therapy for the Treatment of Osteoporosis

Also Published As

Publication numberPublication date
EP1210138A4 (en)2003-05-07
CA2370769A1 (en)2000-11-02
EP1210138A1 (en)2002-06-05
WO2000064516A1 (en)2000-11-02

Similar Documents

PublicationPublication DateTitle
AU5914999A (en)Controlled release drug delivery
AU4652100A (en)Controlled delivery of bisphosphonates
AU2492000A (en)Implantable neuro-stimulator
AU3342599A (en)Delivery catheter
AU6168699A (en)Non-compliant system for delivery of implant material
AU5588499A (en)Implant delivery assembly
AU4981200A (en)Stent delivery system
AU5259100A (en)Medicament
AU4139801A (en)Controlled delivery of antigens
AU7059300A (en)Immediate provisional implant
AU6956398A (en)Implant delivery system
AU3007801A (en)Medicament dispenser
AU2509901A (en)Medicament dispenser
AU2212300A (en)Delivery vault
AU6109400A (en)Atomizer system
AU3520900A (en)Implantable drug delivery system
AU1514401A (en)Medicament dispenser
AU7003500A (en)Delivery box
AU5092099A (en)Vibroacoustic delivery system
AU1541601A (en)Syringes
AU5003800A (en)Implant system
AU2331100A (en)Ceramic coating
AU5429699A (en)Drug targeting
AU5745900A (en)Suspoemulsion system for delivery of actives
AUPQ067299A0 (en)Atomiser

Legal Events

DateCodeTitleDescription
MK6Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase

[8]ページ先頭

©2009-2025 Movatter.jp